M. Henry‐Amar

15.0k total citations · 2 hit papers
205 papers, 9.7k citations indexed

About

M. Henry‐Amar is a scholar working on Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, M. Henry‐Amar has authored 205 papers receiving a total of 9.7k indexed citations (citations by other indexed papers that have themselves been cited), including 92 papers in Pathology and Forensic Medicine, 82 papers in Pulmonary and Respiratory Medicine and 62 papers in Oncology. Recurrent topics in M. Henry‐Amar's work include Lymphoma Diagnosis and Treatment (86 papers), Lung Cancer Treatments and Mutations (47 papers) and Multiple and Secondary Primary Cancers (25 papers). M. Henry‐Amar is often cited by papers focused on Lymphoma Diagnosis and Treatment (86 papers), Lung Cancer Treatments and Mutations (47 papers) and Multiple and Secondary Primary Cancers (25 papers). M. Henry‐Amar collaborates with scholars based in France, Netherlands and Belgium. M. Henry‐Amar's co-authors include A.M. Mandard, Patrice Carde, G Samama, J. Marnay, Sylvie Bonvalot, P Ségol, J.-C. Mandard, M Gignoux, Alexandre Roussel and John Jacob and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

M. Henry‐Amar

200 papers receiving 9.4k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations

1994 1.6k citations A.M. Mandard, J. Marnay et al. profile →
Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group.

1996 487 citations A.M. Mandard, M. Henry‐Amar et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
M. Henry‐Amar	3.7k	3.5k	3.3k	2.3k	1.1k	205	9.7k
Lois B. Travis	3.4k 0.9×	4.8k 1.4×	3.4k 1.1×	2.5k 1.1×	1.7k 1.6×	183	14.0k
Rochelle E. Curtis	2.2k 0.6×	4.3k 1.2×	2.7k 0.8×	1.7k 0.7×	2.2k 2.0×	109	11.2k
William T. McGivney	4.6k 1.2×	6.1k 1.7×	1.5k 0.5×	3.1k 1.3×	789 0.7×	30	13.0k
Richard Tsang	1.0k 0.3×	2.5k 0.7×	2.7k 0.8×	2.0k 0.9×	892 0.8×	201	8.3k
Elyn Riedel	4.0k 1.1×	4.5k 1.3×	964 0.3×	3.3k 1.4×	302 0.3×	155	10.4k
E. William St. Clair	3.0k 0.8×	1.2k 0.3×	1.7k 0.5×	964 0.4×	3.2k 2.9×	170	16.5k
Carlomaurizio Montecucco	1.2k 0.3×	799 0.2×	1.4k 0.4×	1.3k 0.6×	1.9k 1.7×	436	9.9k
Lindsay M. Morton	945 0.3×	3.9k 1.1×	4.4k 1.4×	684 0.3×	1.0k 0.9×	205	9.5k
Umberto Tirelli	1.2k 0.3×	5.6k 1.6×	4.2k 1.3×	815 0.4×	315 0.3×	405	10.1k
Israel Penn	1.7k 0.4×	5.4k 1.6×	1.2k 0.4×	3.7k 1.6×	475 0.4×	210	11.6k

Countries citing papers authored by M. Henry‐Amar

Since Specialization

Citations

This map shows the geographic impact of M. Henry‐Amar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Henry‐Amar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Henry‐Amar more than expected).

Fields of papers citing papers by M. Henry‐Amar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Henry‐Amar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Henry‐Amar. The network helps show where M. Henry‐Amar may publish in the future.

Co-authorship network of co-authors of M. Henry‐Amar

This figure shows the co-authorship network connecting the top 25 collaborators of M. Henry‐Amar. A scholar is included among the top collaborators of M. Henry‐Amar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Henry‐Amar. M. Henry‐Amar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kiciński, Michal, Marleen A. E. van der Kaaij, Francesco Giusti, et al.. (2022). Employment situation among long-term Hodgkin lymphoma survivors in Europe: an analysis of patients from nine consecutive EORTC-LYSA trials. Journal of Cancer Survivorship. 18(3). 727–738. 4 indexed citations

Noordijk, Evert M., Patrice Carde, N. Dupouy, et al.. (2006). Combined-Modality Therapy for Clinical Stage I or II Hodgkin's Lymphoma: Long-Term Results of the European Organisation for Research and Treatment of Cancer H7 Randomized Controlled Trials. Journal of Clinical Oncology. 24(19). 3128–3135. 149 indexed citations

Switsers, O., et al.. (2006). Clinical impact of fluorine-18 fluorodeoxyglucose positron emission tomography in cancer patients. A comparative study between dedicated camera and dual-head coincidence gamma camera.. PubMed. 50(1). 68–77. 2 indexed citations

Jong, Daphne de, J. Bosq, KA MacLennan, et al.. (2005). Lymphocyte-rich classical Hodgkin lymphoma (LRCHL): clinico-pathological characteristics and outcome of a rare entity. Annals of Oncology. 17(1). 141–145. 18 indexed citations

Aleman, Berthe M.P., M. Henry‐Amar, Umberto Tirelli, et al.. (2001). Involved field irradiation (IFRT) does not improve outcome in patients with stage III/IV Hodgkin's lymphoma (HL) in complete remission after MOPP/ABV (M/A): Results of the randomised EORTC trial 20884. Blood. 98(11). 6 indexed citations

Flechtner, Hans‐Henning, Jens Ulrich Rüffer, M. Henry‐Amar, et al.. (1998). Quality of life assessment in Hodgkin’s disease: A new comprehensive approach. Annals of Oncology. 9. s147–s154. 27 indexed citations

Bardet, É., Alain Rivière, Anne Charloux, et al.. (1997). A phase II trial of radiochemotherapy with daily carboplatin, after induction chemotherapy (carboplatin and etoposide), in locally advanced nonsmall-cell lung cancer: Final analysis. International Journal of Radiation Oncology*Biology*Physics. 38(1). 163–168. 8 indexed citations

Cosset, J M & M. Henry‐Amar. (1997). Maladie de Hodgkin. Les complications à long terme de la radiothérapie.. La Presse Médicale. 26(23). 3 indexed citations

Chaplain, Gilles, Pascale Grosclaude, P. Arveux, et al.. (1997). Les cancers génitaux et mammaires féminins en France : répartition géographique et estimation de l’incidence. Bulletin du Cancer. 84(10). 0–0. 4 indexed citations

10.

Lebailly, Pierre, C. Vigreux, Thierry Godard, et al.. (1997). P XVI A.12 Use of alkaline comet assay to detect DNA damages in mononuclear leukocytes of farmers occupationally exposed to pesticides. Mutation research. Fundamental and molecular mechanisms of mutagenesis. 379(1). S157–S157. 1 indexed citations

11.

Henry‐Amar, M. & Florence Joly. (1996). Late complications after Hodgkin's disease. Annals of Oncology. 7. S115–S126. 50 indexed citations

12.

Salmerón, S., Laurent Brochard, Hervé Mal, et al.. (1994). Nebulized Versus Intravenous Albuterol in Hypercapnic Acute Asthma. A Multicenter, Double-Blind, Randomized Study. American Journal of Respiratory and Critical Care Medicine. 149(6). 1466–1470. 70 indexed citations

13.

Somers, R., Patrice Carde, M. Henry‐Amar, et al.. (1994). A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial.. Journal of Clinical Oncology. 12(2). 279–287. 73 indexed citations

14.

Angevin, Eric, Françoise Farace, Catherine Genevée, et al.. (1993). Analysis of T‐cell‐receptor variable gene segment usage in peripheral‐blood lymphocytes of advanced cancer patients. International Journal of Cancer. 54(1). 60–67. 7 indexed citations

15.

Löffler, Markus, Peter Mauch, KA MacLennan, Lena Specht, & M. Henry‐Amar. (1992). The Second International Symposium on Hodgkin's Disease. Workshop I: Review on prognostic factors.. PubMed. 3 Suppl 4. 63–6. 6 indexed citations

16.

Henry‐Amar, M., Samuel Friedman, Marcel Hayat, et al.. (1991). Erythrocyte Sedimentation Rate Predicts Early Relapse and Survival in Early-Stage Hodgkin Disease. Annals of Internal Medicine. 114(5). 361–365. 67 indexed citations

17.

Henry‐Amar, M., M. Hayat, J.H. Meerwaldt, et al.. (1990). Causes of death after therapy for early stage Hodgkin's disease entered on EORTC protocols. International Journal of Radiation Oncology*Biology*Physics. 19(5). 1155–1157. 80 indexed citations

18.

Jayr, Christian, et al.. (1988). Postoperative pulmonary complications: general anesthesia with postoperative parenteral morphine compared with epidural analgesia.. PubMed. 104(1). 57–63. 54 indexed citations

19.

Jungers, P, M. Henry‐Amar, G Albouze, et al.. (1986). Chronic kidney disease and pregnancy.. PubMed. 15. 103–41. 63 indexed citations

20.

Tubiana, M, et al.. (1977). [Treatment of clinical stages I and II of Hodgkin's disease].. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 18(2). 463–72. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact